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letter to the Editor B-type natriuretic peptide for the prediction of left ventricular remodelling dear sir
We read with great interest the recent article by Choi et al. 1 on the optimal time of B-type natriuretic peptide (BNP) sampling for the prediction of left ventricular (LV) remodelling after myocardial infarction (MI). Indeed, as underscored by Choi et al., LV remodelling remains a significant clinical problem in the modern era of MI management. 2 In addition, BNP is currently the sole biomarker that has been convincingly associated with LV remodelling in multiple studies (reviewed in Fertin et al. 3 ). It is therefore important to determine the best window of time for its determination in clinical practice.
Using multivariate analysis in a cohort of 131 patients, the authors found that early levels (two to five days) of BNP were associated with LV remodelling in fully adjusted models, whereas late (three to four weeks) and long-term (six months) levels were not. We previously reported on the usefulness of serial (three to seven days, one, three and 12 months) assessment of BNP to predict LV remodelling after MI in a prospective study of 246 patients with a first anterior Q-wave MI. 4 Our results, which were at variance from those of the study by Choi et al., demonstrated that BNP levels at any time point were associated with LV remodelling; the association was mild at baseline and stronger during follow up, particularly after three months.
With multivariate analysis, BNP retained its predictive value at one, three and 12 months, but no longer at baseline. These discrepancies between studies may be related to differences in study populations and/or therapeutic management. It is also important to know how missing values were handled when comparing models at different time points. From the data presented by Choi et al., it appears that BNP measurements at six months were lacking in more than 20% of the cases. This could theoretically have 'disadvantaged' BNP in late versus early models.
At present, we believe that the optimal timing after MI for BNP determination in clinical practice remains an unsettled question. 
